MTT #109: Healthcare affordability, GLP-1s and the patient revolt ahead

In this week’s episode of Medicine: The Truth, hosts Jeremy Corr and Dr. Robert Pearl dig for the facts beneath healthcare’s biggest headlines. Today’s show opens with the issue most likely to shape how Americans think about healthcare heading into the midterm elections: affordability.

Dr. Pearl explains that medical costs have now reached $5.7 trillion, rising more than 7% for the third consecutive year. Federal actuaries project that healthcare spending could approach $9 trillion by 2034, accounting for more than 20% of the U.S. GDP. For voters, employers, patients and families, those numbers aren’t just an endless string of zeroes. They’re impacting everyday life.

Premiums, deductibles, copays and prescription drug costs are forcing people with private insurance, Medicare and exchange coverage to delay care, take on debt or choose worse coverage. Two major drivers stand out: hospital spending and drug costs. Hospital care remains the largest share of national healthcare expenses, while drug spending is rising fastest, driven in part by the growing use of GLP-1 medications. Pearl sees enormous potential in these drugs to improve health and reduce complications over time, but only if prices fall low enough for the long-term savings to justify the near-term expense.

That tension becomes clearer in the discussion of Medicare’s new GLP-1 pilot program for weight loss. Under the “bridge program,” eligible Medicare enrollees will be able to obtain GLP-1 medications for $50 a month, far below current retail prices. Pearl calls the program an important experiment, but also notes its limitations: coverage is not automatic, eligibility is restricted, administrative hurdles remain and the pilot may end after 18 months. If patients lose access and regain weight, the program could fail despite the promise of the medication.

The episode then moves into several unusual and important stories, including new research into the origins of life, the medical risks of cannibalism, the promise and limitations of wearable health data, a large cyclosporiasis outbreak, rising e-bike injuries among children and adolescents, a new cholesterol-lowering pill, CDC leadership and measles.

Here are the major storylines from episode 109:

Researchers studying the origin of life made progress by taking a counterintuitive approach: building a synthetic cell from simple inorganic materials rather than stripping existing life forms down to their minimum parts.

“Spud cell” research could eventually help scientists understand which genes are essential and create engineered cells capable of producing new medical treatments.

A new study suggests cannibalism may have disappeared in part because of medical consequences, including infections and prion diseases that harmed tribes practicing it.

Wearable devices are generating valuable health data, but most doctors lack the time, reimbursement and regulatory pathways needed to integrate that information into clinical care.

A large cyclosporiasis outbreak has raised concerns about foodborne illness surveillance, produce safety and the difficulty of identifying contamination sources when symptoms appear one to two weeks after exposure.

E-bike injuries are rising, especially among children and adolescents, with head, face and neck injuries posing particular concern.